Matrix metalloproteinase-9 in spontaneously hypertensive hyperlipidemic rats

Pathophysiology

Volumn 15, Issue 3, 2008, Pages 157-166

  Asano, Yasuhiko ^a   Iwai, Shinichi ^a   Okazaki, Masako ^a   Kumai, Toshio ^b   Munemasa, Yasunari ^b   Oonuma, Shigeko ^b   Tadokoro, Mamoru ^b   Kobayashi, Shinichi ^b   Oguchi, Katsuji ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hyperlipidemia; Hypertension; Matrix metalloproteinases (MMPs); Retina; Spontaneously hypertensive hyperlipidemic rats (SHHRs); Vitreous

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HYPERLIPIDEMIA; HYPERTENSION; HYPERTENSION RETINOPATHY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA; RETINA MACULA VITELLIFORM DEGENERATION; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; VITREOUS BODY; WISTAR KYOTO RAT;

EID: 50249148318     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2007.02.001     Document Type: Article

References (46)

1. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90 (1994) 2126-2146
2. Joensuu T., Salonen R., Winblad I., Korpela H., and Salonen J.T. Determinants of femoral and carotid artery atherosclerosis. J. Int. Med. 236 (1994) 79-84
3. Wong Larsen E.K., Klein R., Mitchell P., Couper D.J., Klein B.E., Hubbard L.D., Siscovick D.S., and Sharrett A.R. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the atherosclerosis risk in communities & cardiovascular health studies. Ophthalmology 112 (2005) 540-547
4. Walsh J.B. Hypertensive retinopathy. Description, classification, and prognosis. Ophthalmology 89 (1982) 1127-1131
5. Wong T.Y., and Mclntosh R. Hypertensive retinopathy signs as risk indicators of cardiovascular morbidity and mortality. Br. Med. Bull. 73 (2005) 57-70
6. Watanabe M., Nakura H., Tateishi T., Tanaka M., Kumai T., and Kobayashi S. Reduced hepatic drug-metabolizing enzyme activities in spontaneously hyperlipidemic rat as an animal model of hypercholesterolaemia. Med. Sci. Res. 24 (1996) 257-259
7. Kumai T., Oonuma S., Kitaoka Y., Tadokoro M., and Kobayashi S. Biochemical and morphological characterization of spontaneously hypertensive hyperlipidaemic rats. Clin. Exp. Pharmacol. Physiol. 30 (2003) 537-544
8. Kumai T., Oonuma S., Matsumoto N., Takeba Y., Taniguchi R., Kamio K., Miyazu O., Koitabashi Y., Sekine S., Tadokoro M., and Kobayashi S. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia. Life Sci. 74 (2004) 2129-2142
9. Nagase H., and Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 274 (1999) 21491-21494
10. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell. Biol. 74 (1997) 111-122
11. Zeng B., Prasan A., Fung K.C., Solanki V., Bruce D., Freedman S.B., and Brieger D. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern. Med. J. 35 (2005) 331-335
12. Yasmin, McEniery C.M., Wallace S., Dakham Z., Pusalkar P., Maki-Petaja K., Ashby M.J., Cockcroft J.R., and Wilkinson I.B. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 372-378
13. Lambert V., Wielockx B., Munaut C., Galopin C., Jost M., Itoh T., Werb Z., Baker A., Libert C., Krell H.W., Foidart J.M., Noel A., and Rakic J.M. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am. J. Pathol. 161 (2002) 1247-1253
14. Minami M., Hasebe Y., Nakanishi-Ueda T., Iwai S., Ueda T., Dorey C.K., Oguchi K., Hajime Y., and Koide R. Inhibition of oxygen-induced retinal neovascularization in the neonatal rat by green tea extract. J. Clin. Biochem. Nutr. 33 (2003) 23-31
15. Iwai S., Aljada A., Higa A., Nakanishi-Ueda T., Fukuda S., Kamegawa M., Iwabuchi S., Ueda T., Caballero S., Browne R., Afzal A., Grant M., Yasuhara H., Koide R., Oguchi K., Dandona P., and Armstrong D. Activation of AP-1 and increased synthesis of MMP-9 in the rabbit retina induced by lipid hydroperoxide. Curr. Eye Res. 31 (2006) 337-346
16. Gomibuchi H., Okazaki M., Iwai S., Kumai T., Kobayashi S., and Oguchi K. Development of hyperfibrinogenemia in spontaneously hypertensive and hyperlipidemic rat: a potentially useful animal model as a complication of hypertension and hyperlipidemia. Exp. Anim. 56 (2007) 1-10
17. Amagasa H., Okazaki M., Iwai S., Kumai T., Kobayashi S., and Oguchi K. Enhancement of the coagulation system in spontaneously hypertensive and hyperlipidemic rats. J. Atheroscler. Thromb. 12 (2005) 191-198
18. Zhang X., Sakamoto T., Hata Y., Kubota T., Hisatomi T., Murata T., Ishibashi T., and Inomata H. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp. Eye Res. 74 (2002) 577-584
19. Sasaki K., Hattori T., Fujisawa T., Takahashi K., Inoue H., and Takigawa M. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J. Biochem. 123 (1998) 431-439
20. Van Leiden H.A., Dekker J.M., Moll A.C., Nipels G., Heine R.J., Bouter L.M., Stehouwer C.D., and Polak B.C. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn Study. Diabetes Care 25 (2002) 1320-1325
21. Wong T.Y., Duncan B.B., Golden S.H., Klein R., Couper D.J., Klein B.E., Hubbard L.D., Sharret A.R., and Schmidt M.I. Associations between the metabolic syndrome and retinal microvascular signs: the atherosclerosis risk in communities study. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2949-2954
22. Sabbatini M., Tomassoni D., Di Tullio M.A., and Amenta F. Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clin. Exp. Hypertens. 24 (2002) 727-740
23. Kagsburn M., and Moses M.A. Molecular angiogenesis. Chem. Biol. 6 (1999) R217-R224
24. Chao Han Z., and Liu Y. Angiogenesis: state of the art. Int. J. Hematol. 70 (1999) 68-82
25. Gibbsons G.H., and Dzau V.J. The emerging concept of vascular remodeling. N. Engl. J. Med. 330 (1994) 1431-1438
26. Bendeck M.P., Zempo N., Clowes A.W., Galardy R.E., and Reidy M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 75 (1994) 539-545
27. Godin D., Ivan E., Johnson C., Magid R., and Galis Z.S. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 102 (2000) 2861-2866
28. Allaire E., Hasenstab D., Kenagy R.D., Starcher B., Clowes M.M., and Clowes A.W. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 98 (1998) 249-255
29. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., and Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110 (2002) 625-632
30. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., Arveiler D., Luc G., Cambien F., Hamstein A., Watkins H., and Henney A.M. Functional polymorphism in the region of geratinase B gene in relation to severity of coronary atherosclerosis. Circulation 99 (1999) 1788-1794
31. Medley T.L., Cole T.J., Dart A.M., Gatzka C.D., and Kingwell B.A. Matrix metalloproteinase-9 influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1-6
32. Blankenberg S., et al. Plasma concentrations and genetic variation of matrix metalloproteinase-9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
33. Motaner J., Molina C.A., Monasterio J., Abilleira S., Arenillas J.F., Ribo M., Quintana M., and Alvares-Sabin J. Matrix metalloproteinase-9 pretreatment levels predicts intracranical hemorrhagic complications after thrombolysis in human stroke. Circulation 107 (2003) 598-603
34. De La Paz M.A., Itoh Y., Toth C.A., and Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest. Ophthalmol. Vis. Sci. 39 (1998) 1256-1260
35. Jin M., Kashiwagi K., Iizuka Y., Tanaka Y., Imai M., and Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21 (2001) 28-33
36. Kon C.H., Occleston N.L., Charteris D., Daniels J., Aylward G.W., and Khaw P.T. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 39 (1998) 1524-1529
37. Grant M.B., Caballero S., Tarnuzzer R.W., Bass K.E., Ljubimov A.V., Spoerri P.E., and Galardy R.E. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 47 (1998) 1311-1317
38. Behzadian M.A., Wang X., Windsor L.J., Ghaly N., and Caldwell R.B. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: Possible role of glial cells in endothelial barrier function. Invest. Ophthalmol. Vis. Sci. 42 (2001) 853-859
39. Bergers G., Brekken R., Mcmahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., and Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell. Biol. 2 (2000) 737-744
40. Edelman J.L., Lutz D., and Castro M.R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp. Eye Res. 80 (2005) 249-258
41. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J. Cell. Biochem. 53 (1993) 288-295
42. Harendza S., Pollock A.S., Mertens P.R., and Lovett D.H. Tissue-specific enhancer-promoter interactions regulate high-level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. J. Biol. Chem. 270 (1995) 18786-18796
43. Baramova E., and Foidart J.M. Matrix metalloproteinase family. Cell. Biol. Int. 19 (1995) 239-242
44. Apte S.S., Olsen B.R., and Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J. Biol. Chem. 270 (1995) 14313-14318
45. Lambert E., Dasse E., Haye B., and Petitfrere E. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol. 49 (2004) 187-198
46. 's membrane of the eye. Am. J. Pathol. 150 (1997) 323-328